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Abstract
Antisocial personality disorder (ASPD) is a persistent psychiatric disorder. Behaviors 
and emotions deviate from the norm. Inherent impulsivity, comorbid alcohol depen-
dence, and violation of laws cause severe challenges at individual and societal levels. 
Both environment and heritability alter the risk for ASPD. Research shows that specific 
biologic changes predispose to this disorder. Biological factors may lead to novel possi-
bilities to treat and alleviate symptoms with medications or nutritional means. However, 
treatment of ASPD meets particular challenges due to the inherent symptoms of the dis-
order, and firm evidence-based personalized treatments are scant. This chapter describes 
the disorder and associated adverse outcomes in life such as recurrent violent behavior 
and increased mortality. Moreover, treatment possibilities are discussed covering risk 
assessment, medication, psychotherapy, and nutrition.
Keywords: antisocial personality disorder, ASPD, alcoholism, impulsivity, violent 
behavior
1. Introduction
Antisocial personality disorder (ASPD) is a psychiatric disorder, which despite being prob-
ably heavily under diagnosed has at least a prevalence of 1 in 100 persons [1]. The golden 
standard of treatment of psychiatric disorders is a combination of pharmacological treatment 
and psychotherapy. To date, there are no specific golden standards of pharmacological or 
psychotherapeutic treatments of ASPD, but in the future, treatment results may improve 
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after careful selection of whom to treat. ASPD forms a patient group, which has a poor treat-
ment compliance in general due to inherent diagnostic symptoms of unplanned lifestyle and 
impulsive decision-making.
2. What is ASPD: what to treat
The core symptoms of ASPD are antisocial attitudes that lead to generally destructive behavior 
in part due to the inherent impulsive behavior and severe alcoholism (early-onset type II alco-
holism) associated with this disorder. ASPD is diagnosed among adults, but it is preceded by 
conduct disorder symptoms before age 15, symptoms such as running away from home, initia-
tion of physical fights, usage of weapons in fights, forcing others into sexual activity, cruelty to 
animals, destruction of other persons’ property, deliberately engaged in fire-setting, frequent 
lying, and stealing. An extensive description of conduct disorder, however, is beyond the scope 
of this article.
Diagnostic symptoms of ASPD have not changed much over time. The symptom cluster 
includes the following type of items [2]:
• Inability to sustain consistent work or studies due to lack of motivation, repeated absence 
from work, impulsive abandonment of several jobs without realistic plans of future jobs or 
education.
• Failure to conform to social norms with respect to lawful behavior, as indicated by repeat-
edly performing acts that are grounds for arrest (whether arrested or not), e.g., destroying 
property, harassing others, stealing, and pursuing an illegal occupation.
• Irritability and aggressiveness, as indicated by repeated physical fights or assaults.
• Repeatedly failing to honor financial obligations, as indicated by defaulting on debts or 
failing to provide child support on regular basis.
• Impulsive behavior and inability to plan ahead, as indicated by, e.g., traveling from place 
to place without a prearranged job or clear goal for the period of travel or clear idea about 
when the travel will terminate and lack of a fixed address for a long period.
• No respect for the truth as indicated by repeated lying, use of aliases, and “conning” others 
for personal profit or pleasure.
• Recklessness regarding own or others’ safety, as indicated by driving while intoxicated or 
recurrent speeding.
• If being a parent or guardian, lacks ability to function as a responsible parent, as indicated 
by, for instance, malnutrition of child, child’s illness resulting from lack of minimal hy-
giene, child’s dependence on neighbors or nonresident relative for food or shelter, failure 
to arrange for a caretaker for your child when parent is away from home, and repeated 
squandering on personal items or of money required for household necessities.
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• Never sustained a totally monogamous relationship for more than 1 year.
• Lacks remorse (feels justified in having hurt, mistreated, or stolen from others).
Realistic foci of treatment for persons diagnosed with ASPD are (i) modulation of attitudes, 
(ii) decrease of impulsive behavior, and (iii) treatment of alcoholism.
3. Personalized focus and selection of whom to treat
As patient care resources and skills to treat specifically ASPD are limited, there is a strong 
rationale to carefully choose the target groups of individuals suffering from ASPD, whom 
should persistently be encouraged and motivated to treatment. For this, two separate ways 
of selective approach may be adapted, each focusing on different criteria. One alternative for 
selection of whom to treat in this patient group would be a focus in primary prevention when 
the first symptoms appear and accumulate (early interventions). Another focus is secondary 
prevention and treatment when the first tangible severe consequences of having ASPD appear.
Some of the more obvious measurement tools that could be considered for the decision-
making on whether to start an intervention or not would be presence of persistent alcohol 
consumption and conduct disorder symptoms appearing at an early age (age 10–14) or acts 
leading to a prison sentence. An act of violence that leads to a prison sentence is unfortunately 
frequent among ASPD patients in early adulthood preceded by several smaller violations of 
the law not leading to incarceration. However, in the incarcerated environment, a meaning-
ful secondary prevention effort can be arranged. As 50% of prison populations are diagnosed 
with ASPD [3], it is unrealistic to provide treatment for all ASPD patients, but a good rationale 
for focus would be those individuals who are at an increased risk for reoffenses.
Decisions for offering treatments are dichotomous but symptoms and risk are often measured 
on a continuum from mild to severe. However, scales of symptom and risk severity can easily 
be constructed, and often a meaningful cutoff point, depending on the size of the selection 
population, is the 75–90% percentile. Continuums such as alcohol consumption quantity, trait 
impulsivity, and accumulation of acts of violent can be transformed into categories of high-
low expected efficacy of treatment for the individual or high-low expectancy of benefit for 
society. Both interests are often in line with each other.
4. Risk assessment for recurrent violent behavior or premature death
The tools for assessing risk for future acts of violence in previously violent populations have 
been criticized as an inexact science [4]. Many attempts of constructing assessment tools have 
been made, but their accuracy is far from satisfactory. For instance, the risk assessment tools 
HCR-20 and PCL-R rely on psychological assessments and historical data on life events, 
which may be difficult to assess. Moreover, application of such tool needs highly trained 
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professionals. The accuracy of such assessments suffers from several sources of bias such 
as underlying biologic individual variation [5]. Likewise, childhood maltreatment may also 
have ambiguous inter-rater variations and compromised data source reliability. However, 
childhood maltreatment has been unambiguously assessed to increase the risk for antisocial 
behavior, recurrent violent behavior, and premature death at the age of 40, especially in com-
binations with biological variations (e.g., different monoamine oxidase A genotypes) leading 
to alteration of risk [6–8]. Alcohol consumption has shown a positive correlation with increase 
in risk for recurrent acts of violence, whereas aging has shown to have a negative correlation 
to this outcome measure [9]. The biologic field of research may have most new tools to con-
tribute to risk assessments in the future.
The biological research in violent reconvictions may reveal new possibilities to pharmacologi-
cal treatments of ASPD and support decisions on whom to treat. The method for obtaining 
reliable scientific evidence of causalities leading to recurrent violent behavior is conducting 
long follow-up study settings in large cohorts. Both ASPD and severe alcoholism are consid-
ered hereditary. A consensus approximation of the hereditary component of alcoholism is 
50% [10]. Impulsivity as a persistent tendency to act on the spur of the moment or locomo-
tive restlessness are also partly hereditary [11]. Detection of genetic causalities underlying 
ASPD, severe alcoholism, and impulsivity has to date resulted in a handful of robust find-
ings mainly through utilization of violent alcoholics in a young Finnish founder population. 
Genetic research in founder population allows an increased power to detect specific genetic 
risk for complex disorders due to a relatively homogenous gene pool caused by geographic 
isolation [12]. Six ASPD-impulsivity-alcoholism-violence-related genes have been detected 
in the Finnish founder population. These genes comprise the serotonin 2B receptor (HTR2B) 
[13], tryptophan hydroxylase 2 (TPH2) [14], serotonin 1B receptor (HTR1B) [15], serotonin 3B 
receptor (HTR3B) [16], monoamine oxidase A (MAOA) [7, 9, 17], and T-cadherin [17].
Apart from specific genes, variation in glucose and insulin metabolism, which could be 
regarded as biomarkers, has also been shown to robustly predict recurrent violent behavior 
[18, 19]. Likewise, low serotonin levels have also been robustly associated with impulsive-
aggressive behavior [20, 21].
Detection of individuals with high risk, especially due to biologic reasons, may raise ethical 
issues whether to treat or isolate individuals with increased risk for recurrent violent behav-
ior. However, for medical professionals, the importance of treatment efforts of the psychiatric 
disorder ASPD, alcoholism, and overt impulsivity is clear as treatment is offered for other 
diseases with underlying biologic causalities such as diabetes or strokes, as well.
5. Medication
Impulsivity and alcoholism frequently coexist. Consequently, treatment of either symptom or 
disorder alleviates the other. The treatment of alcoholism is more advanced compared with 
treatment of impulsivity. At best, specific genetic data may reveal who will benefit from a spe-
cific treatment in a dichotomous manner. A prime example of this is that individuals having 
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a specific gene variant (Asp40) in the μ-opioid receptor (OPRM1) seem to clearly benefit from 
naltrexone treatment of alcoholism, whereas individuals with another genetic variant do not 
benefit from this medication [22]. Although there is a paucity of studies with such clear evi-
dence of one gene’s effect on a particular pharmacological treatment, this is the direction 
research should move into. Kupila et al. [23] recently found that the severity of alcoholism 
(Cloninger’s type I vs. type II) alters pharmacological binding to the glutamate system, which 
is associated with addictions. Such findings give clues for meaningful study-setting which 
could contribute to future evidence-based personalized medical management. The severity of 
alcoholism has also been examined as a predictor in some pharmacological studies. It seems 
that patients with severe alcohol dependence (type II), which is associated with ASPD, may 
react differently to medications as compared with patients with the less severe form of alco-
holism (type I), which is the type of alcohol dependence that the majority of “alcoholics” suf-
fer from. For instance, antagonism of the serotonin 3 receptor with ondansetron has shown 
beneficial in the treatment of early onset severe alcoholism (type II), whereas no considerable 
therapeutic effect appears among patients with less severe alcoholism [24].
Moreover, having a loss-of-function point mutation allele of the serotonin 2B receptor (HTR2B 
Q20*) propagates focused treatment of alcoholism and impulsivity as this mutation has been 
shown to make the carriers of this mutation more susceptible for problem-behavior especially 
while under the influence of alcohol, but also while sober [25]. However, this point mutation in 
the serotonin 2B receptor has only been found among Finns at this point, but this may serve as 
an example of a functional genetic discovery, which may lead to development of personalized 
treatments. Widely used serotonin selective reuptake inhibitors (SSRIs), such as fluoxetine and 
citalopram, do not seem to decrease depression or suicide rates among human HTR2B Q20* 
carriers or Htr2b knockout mice [26, 27]. Therefore, SSRIs likely show no effect on HTR2B Q20* 
ASPD carriers, but new pharmacological strategies are being currently developed [28].
Due to a lack of highly efficient pharmacological treatment of impulsivity and aggression, 
a vast variety of psychopharmacotropics have been used for treatment of impulsivity and 
aggression. However, recent research both in animal study settings [29] and large human 
follow-up cohorts [30] suggests that lithium could be the drug of choice for preventative treat-
ment of impulsive behavior, due to the associated lower risk of suicide attempts and signifi-
cantly decreased suicide mortality, in comparison to valproic acid and benzodiazepines, in 
high-risk bipolar patients [30].
6. Psychotherapy
Psychotherapy aims at alleviating various symptoms, modulate thought constructs, and to 
gain control of behavior such as antisocial attitudes, drinking alcohol, or acting impulsively. A 
slight pessimism regarding the efficacy of psychotherapy in treating ASPD is frequent among 
clinicians, which is partly justified as antisocial thought constructs and impulsive behavior 
decrease treatment compliance. Persons suffering from personality disorders tend to have 
difficulties to realize or admit that they have a mental health problem that would need treat-
ment. This is especially true for ASPD. However, this pessimism for the efficacy of treatment 
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is not justified for all ASPD patients. For instance, group-based cognitive and behavioral inter-
ventions focused on reducing offending and other antisocial behaviors in an optimistic and 
trusting context have shown some good results [31]. It is also important not to have to ambi-
tious goals, but to aim at alleviating some symptoms such as impulsive behavior, decrease in 
alcohol consumption, and decrease in disrespect of the rights of others. Clinical experience 
in the field of forensic psychiatry suggests that life events such as coming into religious faith 
and commitment to a strong-willed spouse would represent a “natural” psychotherapy alter-
ing thought constructs and behavior, and it has proved to be helpful for some ASPD patients. 
Consequently, simple psychotherapeutic themes in treatment of ASPD would be discussing 
religious interests and the benefits of being in a stable long-term relationship.
7. Nutrition
There is no convincing robust scientific evidence for treating ASPD with specific diets alone, but 
the inherent impulsivity and lack of persistence in ASPD certainly cause poor dietary habits. 
Many vitamins and other compounds received through food are vital for the proper biologic 
and physiologic functioning of the body. Thus, it is likely—and a fair hypothesis—that specific 
diets and supplements may show beneficiary for the treatment of ASPD with associated symp-
toms in the future as a part of the treatment strategy. One randomized placebo- controlled 
study suggests that the influence of supplementary vitamins, minerals, and essential fatty acid 
would decrease antisocial behavior and violence in an incarcerated context [32]. These kinds of 
study settings should be replicated and performed in outpatient study settings.
Some general advice, although speculative, on what diet to recommend for ASPD individuals 
could be mentioned. As low serotonin levels have been coupled with impulsivity and aggres-
sion [20, 21], a tangible means of ensuring a sufficient supply of tryptophan in the diet would 
be consumption of cheese and peanuts. When an alcoholic is being in a prolonged relapse 
period of drinking, it may be a good advice to make sure to eat glucose-rich food, as low 
glucose levels have been associated to violent and irritable behavior [20]. On the other hand, 
a glucose-rich diet may be harmful in the long run as it increases the risk for type 2 diabetes, 
and high insulin levels have been associated with increased risk for acts of violence [18].
8. Conclusions and future direction
As most of the acts of violence in the western world are attributable to individuals having 
ASPD, enhancement of the treatment of ASPD will have tangible effects in terms of reduc-
tion of violence in society. Most new ground is expected to be gained through an increase of 
the understanding of the biologic causes of this disorder, which will help decision-making to 
focus and personalize treatments. Combination of several treatment strategies likely amounts 
in best treatment results. As treatment is challenging, professionals should be trained to treat 
this specific patient group. Furthermore, clinicians—including general practitioners—would 
need education in recognizing symptoms associated with ASPD and encouragement to refer 
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these patients to specialized treatment, although the problem remains that ASPD patients 
rarely seek treatment due to the inherent nature of the disorder. Conclusively, it should be 
noted that research supporting evidence-based personalized treatment of ASPD is sparse. 
This review therefore reflects the clinical and theoretical expertise of the author, which hope-
fully could initiate further research.
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